As these factors are inextricably linked to the inflammatory and fibrotic process in diabetic nephropathy, it would suggest that SGLT2 inhibitors may be useful in limiting glucose induced renal inflammation above and beyond its serum glucose lowering effects. This evidence concerns the gene SLC5A2 and diabetic kidney disease.